Ligand Pharmaceuticals Incorporated LGND partner TG Therapeutics,
Inc. TGTX today announced the first presentation of preclinical data
demonstrating single agent and combination activity of two of TG Therapeutics'
IRAK4 inhibitor compounds under development. This pre-clinical data was
presented yesterday at the 106th Annual Meeting of the American Association
for Cancer Research (AACR), held in Philadelphia, PA.
Highlights and conclusions of the study include:
* Both compounds are potent inhibitors of IRAK4 with single-digit nanomolar
potency.
* Data demonstrated IRAK4 inhibitors inhibited cell proliferation and
induced apoptosis as single agents in various B-cell lymphoma cell lines,
potentially elucidating the mechanism of action of and clinical rationale
for IRAK4 inhibition.
* Compounds demonstrated marked synergy when combined with the novel
targeted kinase inhibitors TGR-1202, TG Therapeutics' proprietary PI3K
delta inhibitor, and the BTK inhibitor, ibrutinib.
"We entered into our IRAK-4 partnership with TG Therapeutics last year knowing
the promise of IRAK-4 as a target in both oncology and inflammation, as well
as the opportunities for treatment synergies between IRAK-4 inhibitors and
TG's other best-in-class clinical-stage programs," commented Matt Foehr,
President and Chief Operating Officer of Ligand Pharmaceuticals. "These
studies now further illustrate that potential, and we congratulate our
partners at TG on their progress as they continue to quickly advance the
IRAK-4 program toward the clinic."
A copy of the presentation is available on the Events page, located within the
Investors & Media section of TG Therapeutics' website at
www.tgtherapeutics.com.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in